AE Wealth Management LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 36.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,482 shares of the medical instruments supplier’s stock after buying an additional 660 shares during the quarter. AE Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $580,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $27,000. OLD Point Trust & Financial Services N A bought a new position in Becton, Dickinson and Company during the fourth quarter worth $29,000. Scarborough Advisors LLC acquired a new position in Becton, Dickinson and Company in the fourth quarter worth $32,000. Rise Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth $38,000. Finally, ICA Group Wealth Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth $42,000. Institutional investors own 86.97% of the company’s stock.
Wall Street Analyst Weigh In
BDX has been the subject of a number of recent research reports. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI cut their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. The Goldman Sachs Group began coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective for the company. Finally, Citigroup cut their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.
Becton, Dickinson and Company Price Performance
Shares of NYSE BDX opened at $237.26 on Friday. The firm’s 50-day simple moving average is $235.83 and its 200 day simple moving average is $235.49. The stock has a market cap of $68.57 billion, a P/E ratio of 52.01, a P/E/G ratio of 1.92 and a beta of 0.42. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $269.52.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.96 EPS. Equities analysts expect that Becton, Dickinson and Company will post 13.1 EPS for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.60%. The ex-dividend date of this dividend is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
- Five stocks we like better than Becton, Dickinson and Company
- What is the Shanghai Stock Exchange Composite Index?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What does consumer price index measure?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.